Report Overview
1.1 Introduction to Non-alcoholic Fatty Liver Disease & NASH Market
1.2 Non-alcoholic Fatty Liver Disease & NASH Market Definition
1.3 Global Market Overview
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)

2 Executive Summary
2.1 Key Highlights

3 Non-alcoholic Fatty Liver Disease & NASH Industry Overview
3.1 Overview
3.1.1 Risk Factors for NAFLD & NASH
3.1.2 Diagnosis and Staging of NAFLD/NASH
3.1.3 Imaging Assessment of Steatosis
3.1.4 Liver biopsy for NAFLD
3.1.5 A Pragmatic Approach To Diagnosis And Staging Of NAFLD In Clinical Practice
3.2 COVID-19 Impact of Liver Diseases

4 Market Drivers, Restraints and Opportunities
4.1 Overview
4.2 Increase in number of patients affected by NASH
4.3 Rising Healthcare Expenditure
4.4 Rising Studies And Drugs Developments
4.5 Absence Of Low-Cost And Definitive Diagnostic Methods
4.6 Challenge Due To Regulatory Bodies And Drug Approval
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants - Low
4.7.2 Bargaining Power of Suppliers - Low
4.7.3 Bargaining Power of Buyers - Moderate
4.7.4 Threat of Substitutes - Moderate to Low
4.7.5 Competitive Rivalry - High

5 Global Non-alcoholic Fatty Liver Disease & NASH Market Analysis
5.1 Global Market Overview
5.2 Global Market Estimation & Forecast
5.2.1 Pre-COVID Market Analysis
5.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
5.3 Regional Market Analysis
5.3.1 Pre-COVID Market Analysis
5.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.4 Global Market Breakdown by Disease Cause
5.4.1 Pre-COVID Market Analysis
5.4.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.4.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.5 Global Market Breakdown by Drug Type
5.5.1 Pre-COVID Market Analysis
5.5.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.5.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.6 Global Market Breakdown by Sales Channel
5.6.1 Pre-COVID Market Analysis
5.6.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.6.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

6 North America Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.1 North America Market Overview
6.2 North America Market Estimation & Forecast
6.2.1 Pre-COVID Market Analysis
6.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
6.3 North America Market Breakdown by Country
6.3.1 Pre-COVID Market Analysis
6.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.4 North America Market Breakdown by Disease Cause
6.4.1 Pre-COVID Market Analysis
6.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.5 North America Market Breakdown by Drug Type
6.5.1 Pre-COVID Market Analysis
6.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.6 North America Market Breakdown by Sales Channel
6.6.1 Pre-COVID Market Analysis
6.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.7 US Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.7.1 US Market Outlook
6.7.2 Pre-COVID Market Analysis
6.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.8 Canada Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.8.1 Canada Market Outlook
6.8.2 Pre-COVID Market Analysis
6.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

7 Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.1 Europe Market Overview
7.2 Europe Market Estimation & Forecast
7.2.1 Pre-COVID Market Analysis
7.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
7.3 Europe Market Breakdown by Country
7.3.1 Pre-COVID Market Analysis
7.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.4 Europe Market Breakdown by Disease Cause
7.4.1 Pre-COVID Market Analysis
7.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.5 Europe Market Breakdown by Drug Type
7.5.1 Pre-COVID Market Analysis
7.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.6 Europe Market Breakdown by Sales Channel
7.6.1 Pre-COVID Market Analysis
7.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.7 Germany Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.7.1 Germany Market Outlook
7.7.2 Pre-COVID Market Analysis
7.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.8 UK Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.8.1 UK Market Outlook
7.8.2 Pre-COVID Market Analysis
7.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.9 France Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.9.1 France Market Outlook
7.9.2 Pre-COVID Market Analysis
7.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.10 Italy Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.10.1 Italy Market Outlook
7.10.2 Pre-COVID Market Analysis
7.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.11 Spain Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.11.1 Spain Market Outlook
7.11.2 Pre-COVID Market Analysis
7.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.12 Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.12.1 Rest of Europe Market Outlook
7.12.2 Pre-COVID Market Analysis
7.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

8 Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.1 Asia-Pacific Market Overview
8.2 Asia-Pacific Market Estimation & Forecast
8.2.1 Pre-COVID Market Analysis
8.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
8.3 Asia-Pacific Market Breakdown by Country
8.3.1 Pre-COVID Market Analysis
8.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
8.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.4 Asia-Pacific Market Breakdown by Disease Cause
8.4.1 Pre-COVID Market Analysis
8.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.5 Asia-Pacific Market Breakdown by Drug Type
8.5.1 Pre-COVID Market Analysis
8.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.6 Asia-Pacific Market Breakdown by Sales Channel
8.6.1 Pre-COVID Market Analysis
8.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.7 China Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.7.1 China Market Outlook
8.7.2 Pre-COVID Market Analysis
8.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.8 India Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.8.1 India Market Outlook
8.8.2 Pre-COVID Market Analysis
8.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.9 Japan Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.9.1 Japan Market Outlook
8.9.2 Pre-COVID Market Analysis
8.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.10 South Korea Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.10.1 South Korea Market Outlook
8.10.2 Pre-COVID Market Analysis
8.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.11 Australia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.11.1 Australia Market Outlook
8.11.2 Pre-COVID Market Analysis
8.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.12 Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.12.1 Rest of Asia-Pacific Market Outlook
8.12.2 Pre-COVID Market Analysis
8.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

9 LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.1 LAMEA Market Overview
9.2 LAMEA Market Estimation & Forecast
9.2.1 Pre-COVID Market Analysis
9.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
9.3 LAMEA Market Breakdown by Country
9.3.1 Pre-COVID Market Analysis
9.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.4 LAMEA Market Breakdown by Disease Cause
9.4.1 Pre-COVID Market Analysis
9.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.5 LAMEA Market Breakdown by Drug Type
9.5.1 Pre-COVID Market Analysis
9.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.6 LAMEA Market Breakdown by Sales Channel
9.6.1 Pre-COVID Market Analysis
9.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.7 Brazil Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.7.1 Brazil Market Outlook
9.7.2 Pre-COVID Market Analysis
9.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.8 Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.8.1 Saudi Arabia Market Outlook
9.8.2 Pre-COVID Market Analysis
9.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.9 South Africa Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.9.1 South Africa Market Outlook
9.9.2 Pre-COVID Market Analysis
9.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.10 Mexico Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.10.1 Mexico Market Outlook
9.10.2 Pre-COVID Market Analysis
9.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.11 UAE Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.11.1 UAE Market Outlook
9.11.2 Pre-COVID Market Analysis
9.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.12 Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.12.1 Rest of LAMEA Market Outlook
9.12.2 Pre-COVID Market Analysis
9.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

10 Key Company Profiles
10.1 Pfizer Inc Company
10.1.1 Company Snapshot
10.1.2 Company Overview
10.1.3 Company Financial Profile
10.1.4 Company Product Benchmarking
10.1.5 Company Recent Developments
10.2 F. Hoffmann-La Roche Ltd Company
10.2.1 Company Snapshot
10.2.2 Company Overview
10.2.3 Company Financial Profile
10.2.4 Company Product Benchmarking
10.2.5 Company Recent Developments
10.3 Takeda Pharmaceuticals Company
10.3.1 Company Snapshot
10.3.2 Company Overview
10.3.3 Company Financial Profile
10.3.4 Company Product Benchmarking
10.3.5 Company Recent Developments
10.4 Intercept Pharmaceuticals, Inc. Company
10.4.1 Company Snapshot
10.4.2 Company Overview
10.4.3 Company Financial Profile
10.4.4 Company Product Benchmarking
10.5 AstraZeneca Pharmaceuticals Company
10.5.1 Company Snapshot
10.5.2 Company Overview
10.5.3 Company Financial Profile
10.5.4 Company Product Benchmarking
10.5.5 Company Recent Developments
10.6 Novartis Pharmaceutical Company
10.6.1 Company Snapshot
10.6.2 Company Overview
10.6.3 Company Financial Profile
10.6.4 Company Product Benchmarking
10.6.5 Company Recent Developments
10.7 Merck & Co. Company
10.7.1 Company Snapshot
10.7.2 Company Overview
10.7.3 Company Financial Profile
10.7.4 Company Product Benchmarking
10.7.5 Company Recent Developments
10.8 AbbVie Inc Company
10.8.1 Company Snapshot
10.8.2 Company Overview
10.8.3 Company Financial Profile
10.8.4 Company Product Benchmarking
10.8.5 Company Recent Developments
10.9 Gilead Science Inc Company
10.9.1 Company Snapshot
10.9.2 Company Overview
10.9.3 Company Financial Profile
10.9.4 Company Product Benchmarking
10.9.5 Company Recent Developments
10.10 Genfit Biotechnology Company
10.10.1 Company Snapshot
10.10.2 Company Overview
10.10.3 Company Financial Profile
10.10.4 Company Product Benchmarking
10.10.5 Company Recent Developments
10.11 Cardax Inc Pharmaceutical Company
10.11.1 Company Snapshot
10.11.2 Company Overview
10.11.3 Company Financial Profile
10.11.4 Company Product Benchmarking
10.12 Daewoong Co Ltd Company
10.12.1 Company Snapshot
10.12.2 Company Overview
10.12.3 Company Financial Profile
10.12.4 Company Product Benchmarking
10.12.5 Company Recent Developments
10.13 Madrigal Pharmaceuticals, Inc Company
10.13.1 Company Snapshot
10.13.2 Company Overview
10.13.3 Company Product Benchmarking
10.14 Mirum Pharmaceuticals Inc Company
10.14.1 Company Snapshot
10.14.2 Company Overview
10.14.3 Company Recent Developments
10.15 GW Pharmaceuticals Company
10.15.1 Company Snapshot
10.15.2 Company Overview
10.15.3 Company Financial Profile
10.15.4 Company Product Benchmarking
10.15.5 Company Recent Developments

11 Conclusion & Recommendations
11.1.1 Market Share Analysis, 2021,2026 & 2031 (%)

12 Glossary

List of Tables
Table 1. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 2. Global Non-alcoholic Fatty Liver Disease & NASH Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 3. Risk factors for NAFLD & NASH
Table 4. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 5. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 6. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 7. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 8. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 9. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 10. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 11. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 12. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 13. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 14. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 15. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 16. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 17. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 18. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 19. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 20. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 21. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 22. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 23. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 24. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 25. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 26. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 27. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 28. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 29. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 30. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 31. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 32. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 33. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 34. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 35. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 36. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 37. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 38. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 39. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 40. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 41. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 42. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 43. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 44. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 45. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 46. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 47. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 48. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 49. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 50. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 51. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 52. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 53. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 54. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 55. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 56. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 57. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 58. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 59. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 60. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 61. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 62. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 63. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 64. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 65. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 66. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 67. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 68. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 69. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 70. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 71. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 72. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 73. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 74. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 75. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 76. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 77. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 78. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 79. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 80. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 81. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 82. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 83. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 84. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 85. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 86. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 87. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 88. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 89. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 90. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 91. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 92. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 93. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 94. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 95. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 96. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 97. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 98. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 99. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 100. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 101. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 102. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 103. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 104. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 105. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 106. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 107. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 108. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 109. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 110. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 111. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 112. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 113. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 114. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 115. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 116. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 117. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 118. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 119. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 120. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 121. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 122. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 123. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 124. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 125. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 126. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 127. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 128. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 129. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 130. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 131. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 132. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 133. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 134. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 135. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
Table 136. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
Table 137. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
Table 138. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
Table 139. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 140. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)

Please contact our Customer Support Center to get the complete Table of Contents